LivaNova PLCLIVN

LivaNova PLC nudged its full-year 2026 guidance higher on 6 May 2026, telling investors it now expects higher revenue and adjusted diluted EPS than it did three months earlier, but the real numbers still sit in the 10-Q for 31 March 2026: $362.3 million in revenue, $22.3 million in net income, and $0.40 in diluted EPS. Those figures confirm a company that is profitable, cash-generative, and still investing heavily in its future, but the gap between the polished story and the filing reality is wide enough to park a small fleet of delivery vans in.

What LivaNova actually does is design, make, and sell medical devices for cardiopulmonary perfusion and neuromodulation, with a spotlight on the SYMMETRY™ vagus-nerve stimulator for people who have run out of options after multiple failed antidepressant treatments. The product pages and provider materials are polished, the clinical-trial pipeline is real, and the company keeps talking up ‘difficult-to-treat depression’ as if it’s a growth market rather than a label for patients who have exhausted conventional care. Cardiopulmonary perfusion-its bread-and-butter segment-posted an 18.3% revenue jump in Q1 2026 compared with Q1 2025, driven by Essenz™ perfusion systems, consumables demand, and better pricing, so at least one part of the portfolio is humming.

The 10-Q for 31 March 2026 shows assets of $2.52 billion against liabilities of $1.31 billion, leaving $1.21 billion of shareholders’ equity. Operating income was $41.5 million, net cash from operations was $15.2 million, and the company spent $14.3 million on property, plant, and equipment while ploughing $58.7 million into R&D. Diluted EPS clocked in at $0.40 on 55.9 million shares, so the headline is ‘profitable, growing, and still investing,’ but the subtext is ‘a lot of moving parts and not a lot of float.’ The inventory line sits at $165.5 million, up $1.5 million on the quarter, which is either prudent supply-chain management or the corporate equivalent of stockpiling N95 masks for the next pandemic. The board also reminded everyone in a cluster of SEC Form 4 filings on 17 June 2026 that several executives had bought or sold shares, which is standard disclosure but always reads like the inside-baseball version of a family WhatsApp group.

If you want a chart, your renderer will point you to TradingView’s LIVN route, but the file itself will not invent levels or pretend to read candles; it’ll stick to what the evidence shows. The company’s own product rails-its vagus-nerve stimulation pages, the SYMMETRY™ provider materials, and the RECOVER clinical-trial portal-are all public-facing and official, but they don’t change the numbers in the 10-Q. What they do confirm is that LivaNova is still leaning on ‘emerging therapies’ to keep the story alive while the cardiopulmonary side does the heavy lifting on revenue growth. The tension sits in the mismatch: strong cash generation and rising guidance on one side, a single-product neuromodulation story still waiting for scale on the other. What would change the file next? A catalyst from SYMMETRY™-either regulatory approval, a clear commercial launch, or a meaningful data readout from RECOVER-that finally converts the ‘difficult-to-treat’ label into a real revenue line rather than a marketing promise.